Published : 01 Aug 2026
CHICAGO, IL — August 01, 2026 — Aagami, Inc., a premier life sciences management consulting firm based in the Chicago area, announced today that the United States Bankruptcy Court for the District of Delaware has approved an extension of Aagami’s mandate as the advisory, marketing, and sales consultant to the Chapter 7 Trustee for the bankruptcy estate of Cytometix, Inc.
Pursuant to court order, the term of Aagami’s employment on behalf of the Chapter 7 Trustee, George L. Miller, has been officially extended. Under the terms of the retention order, all provisions of Aagami’s consulting agreement with the Trustee remain in full force and effect.
In this ongoing role, Aagami continues to actively lead global market outreach and transaction structuring for the disposition of Cytometix’s core assets, headlined by CMX-020, a first-in-class, non-opioid clinical analgesic candidate (modulating CB1/CB2 and TRPV1 pathways) with Phase 2 clinical data and an established patent estate.
“We are pleased with the Court’s confidence and the continued partnership with the Trustee,” said Dinesh Jain, Founder & CEO of Aagami, Inc. “The global requirement for safe, non-opioid pain therapeutics remains one of the highest priorities across biopharma. With our proven global reach and deal-making track record, Aagami remains committed to identifying the right strategic acquirer to advance the CMX-020 program toward commercial fruition while maximizing recovery for the bankruptcy estate.”
2 post CDA Bids are already under evaluation.Qualified parties seeking information regarding the acquisition of the CMX-020 patent estate, preclinical/clinical data packages, and regulatory files are encouraged to contact Aagami directly at action@aagami.com.
About Aagami, Inc.
Aagami, Inc. is a U.S.-based life sciences consulting firm specializing in cross-border strategic partnerships, licensing, M&A advisory, and distressed biopharma asset monetization. Headquartered in Naperville, a suburb of Chicago, Illinois, with operational reach across the U.S., Europe, India, Japan, and other global biopharma hubs, Aagami assists pharmaceutical, biotech, and medical technology companies, as well as court-appointed fiduciaries, in executing high-value corporate transactions.